AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next
AbbVie shares rose 0.5% to $221.18 midday Tuesday after Health Canada approved its hepatitis C drug Maviret for acute and chronic use. The move follows a nearly 4% stock drop Monday. Investors are watching for AbbVie’s Jan. 14 J.P. Morgan Healthcare Conference appearance and its quarterly earnings expected later in January.